More on CLLS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.38 |
|
|||
| Open | $1.38 | ||||
| 52 Wk High | $37.55 | ||||
| 52 Wk Low | $16.35 | ||||
| Day High | $1.38 | ||||
| Day Low | $1.38 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 16,623 | ||||
- Barclays Double Downgrades Cellectis (CLLS) to Underweight
- Cellectis (CLLS) PT Lowered to $3 at Wells Fargo
- Citizens Downgrades Cellectis (CLLS) to Market Perform
- Cellectis (CLLS) PT Lowered to $8 at Baird
- Cellectis (CLLS) Tops Q2 EPS by 4c
- Prolynx names CFO and CSO to advance obesity drug portfolio
- Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
- Cellectis receives FDA RMAT designation for blood cancer therapy
- Barclays initiates oncology-focused biotechs with positive outlook
- Barclays Starts Cellectis (CLLS) at Overweight
Entities mentioned with CLLS
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- IPO | View Related Stories »
- Citi | View Related Stories »
- ARK | View Related Stories »
- Barclays | View Related Stories »
- Show More...
